These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24580044)

  • 41. Proteomic analysis of liver mitochondria of apolipoprotein E knockout mice treated with metformin.
    Stachowicz A; Suski M; Olszanecki R; Madej J; Okoń K; Korbut R
    J Proteomics; 2012 Dec; 77():167-75. PubMed ID: 22960565
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?
    Yilmaz Y
    Aliment Pharmacol Ther; 2012 Nov; 36(9):815-23. PubMed ID: 22966992
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Non-alcoholic fatty liver].
    Tagle Arrospide M
    Rev Gastroenterol Peru; 2003; 23(1):49-57. PubMed ID: 12768215
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Deciphering non-alcoholic fatty liver disease through metabolomics.
    Cano A; Alonso C
    Biochem Soc Trans; 2014 Oct; 42(5):1447-52. PubMed ID: 25233430
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pathological features of fatty liver disease.
    Yeh MM; Brunt EM
    Gastroenterology; 2014 Oct; 147(4):754-64. PubMed ID: 25109884
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
    Bugianesi E; Gentilcore E; Manini R; Natale S; Vanni E; Villanova N; David E; Rizzetto M; Marchesini G
    Am J Gastroenterol; 2005 May; 100(5):1082-90. PubMed ID: 15842582
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease.
    Pastori D; Polimeni L; Baratta F; Pani A; Del Ben M; Angelico F
    Dig Liver Dis; 2015 Jan; 47(1):4-11. PubMed ID: 25224698
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome.
    Moore JB
    Proc Nutr Soc; 2010 May; 69(2):211-20. PubMed ID: 20158939
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of metformin treatment on circulating osteoprotegerin in patients with nonalcoholic fatty liver disease.
    Sofer E; Shargorodsky M
    Hepatol Int; 2016 Jan; 10(1):169-74. PubMed ID: 26198758
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Bifari F; Manfrini R; Dei Cas M; Berra C; Siano M; Zuin M; Paroni R; Folli F
    Pharmacol Res; 2018 Nov; 137():219-229. PubMed ID: 30359962
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease.
    Kaser S; Ebenbichler CF; Tilg H
    Int J Clin Pract; 2010 Jun; 64(7):968-83. PubMed ID: 20584230
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease.
    Tilg H; Moschen A
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):159-67. PubMed ID: 20485253
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice.
    Tajima K; Nakamura A; Shirakawa J; Togashi Y; Orime K; Sato K; Inoue H; Kaji M; Sakamoto E; Ito Y; Aoki K; Nagashima Y; Atsumi T; Terauchi Y
    Am J Physiol Endocrinol Metab; 2013 Oct; 305(8):E987-98. PubMed ID: 23964070
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Review article: the metabolic syndrome and non-alcoholic fatty liver disease.
    Loria P; Lonardo A; Carulli L; Verrone AM; Ricchi M; Lombardini S; Rudilosso A; Ballestri S; Carulli N
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():31-6. PubMed ID: 16225469
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The clinical aspects of non-alcoholic fatty liver disease.
    Björnsson E
    Minerva Gastroenterol Dietol; 2008 Mar; 54(1):7-18. PubMed ID: 18299664
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Insulin sensitizers for the treatment of non-alcoholic fatty liver disease.
    Ozturk ZA; Kadayifci A
    World J Hepatol; 2014 Apr; 6(4):199-206. PubMed ID: 24799988
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-alcoholic fatty liver disease.
    Tuyama AC; Chang CY
    J Diabetes; 2012 Sep; 4(3):266-80. PubMed ID: 22564417
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Adiponectin and parameters of glucose and lipid metabolism at different clinical and morphological stages of non-alcoholic fatty liver disease in patients with abdominal obesity].
    Komshilova KA; Troshina EA; Ershova EV; Mazurina NV; Platonova NM
    Ter Arkh; 2014; 86(10):27-32. PubMed ID: 25509888
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations.
    Preiss D; Sattar N
    Clin Sci (Lond); 2008 Sep; 115(5):141-50. PubMed ID: 18662168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.